Pharmacology of hallucinations: Several mechanisms for one single symptom?

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Rolland, Benjamin ^a,b   Jardri, Renaud ^a,b   Amad, Ali ^a,b   Thomas, Pierre ^a,b   Cottencin, Olivier ^a,b   Bordet, Régis ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN 2A RECEPTOR; DOPAMINE 2 RECEPTOR; PSYCHOTROPIC AGENT; SEROTONIN 2 ANTAGONIST;

HALLUCINATION; HUMAN; MEDICAL LITERATURE; NEUROBIOLOGY; NONHUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; THEORY; CHEMICALLY INDUCED; GENETICS; METABOLISM; PATHOLOGY;

HALLUCINATIONS; HALLUCINOGENS; HUMANS; PSYCHOTROPIC DRUGS; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84903639424     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/307106     Document Type: Review

References (72)

1. Blom J. D., A Dictionary of Hallucinations 2009 New York, NY, USA Springer
2. van der Gaag M., A neuropsychiatric model of biological and psychological processes in the remission of delusions and auditory hallucinations. Schizophrenia Bulletin 2006 32 supplement 1 S113 S122 2-s2.0-34247481106 10.1093/schbul/sbl027
3. Andreasen N. C., Flaum M., Schizophrenia: the characteristic symptoms. Schizophrenia Bulletin 1991 17 1 27 49 2-s2.0-0026020165
4. David C. N., Greenstein D., Clasen L., Gochman P., Miller R., Tossell J. W., Mattai A. A., Gogtay N., Rapoport J. L., Childhood onset schizophrenia: high rate of visual hallucinations. Journal of the American Academy of Child & Adolescent Psychiatry 2011 50 7 681.e3 686.e3 2-s2.0-79959678640 10.1016/j.jaac.2011.03.020
5. van Os J., Kapur S., Schizophrenia. The Lancet 2009 374 9690 635 645 2-s2.0-68949180394 10.1016/S0140-6736(09)60995-8
6. Lieberman J. A., Stroup T. S., McEvoy J. P., Swartz M. S., Rosenheck R. A., Perkins D. O., Keefe R. S. E., Davis S. M., Davis C. E., Lebowitz B. D., Severe J., Hsiao J. K., Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005 353 12 1209 1223 2-s2.0-25144456112 10.1056/NEJMoa051688 (Pubitemid 41345943)
7. Howes O. D., Kapur S., The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophrenia Bulletin 2009 35 3 549 562 2-s2.0-65349120160 10.1093/schbul/sbp006
8. Abi-Dargham A., Gil R., Krystal J., Baldwin R. M., Seibyl J. P., Bowers M., van Dyck C. H., Charney D. S., Innis R. B., Laruelle M., Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. The American Journal of Psychiatry 1998 155 6 761 767 2-s2.0-0031799667 (Pubitemid 28252654)
9. 1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology 1989 2 3 191 199 2-s2.0-0024473224 (Pubitemid 19248311)
10. 1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacology 1995 121 3 317 322 2-s2.0-0028875147 10.1007/BF02246069
11. 1 receptors tell us? World Psychiatry 2003 2 3 166 171
12. Mahoney J. J. III, Kalechstein A. D., de la Garza R. II, Newton T. F., Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. The American Journal on Addictions 2008 17 2 83 98 2-s2.0-41949125118 10.1080/10550490701861201 (Pubitemid 351507725)
13. Schmitt K. C., Reith M. E. A., Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. Annals of the New York Academy of Sciences 2010 1187 316 340 2-s2.0-77949281313 10.1111/j.1749-6632. 2009.05148.x
14. Seeman P., Schwarz J., Chen J.-F., Szechtman H., Perreault M., McKnight G. S., Roder J. C., Quirion R., Boksa P., Srivastava L. K., Yanai K., Weinshenker D., Sumiyoshi T., Psychosis pathways converge via D2High dopamine receptors. Synapse 2006 60 4 319 346 2-s2.0-33746575616 10.1002/syn.20303 (Pubitemid 44134353)
15. Chou K. L., Messing S., Oakes D., Feldman P. D., Breier A., Friedman J. H., Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clinical Neuropharmacology 2005 28 5 215 219 2-s2.0-27644532055 10.1097/01.wnf.0000180228.77802.32 (Pubitemid 41579618)
16. Seeman P., Weinshenker D., Quirion R., Srivastava L. K., Bhardwaj S. K., Grandy D. K., Premont R. T., Sotnikova T. D., Boksa P., El-Ghundi M., O'Dowd B. F., George S. R., Perreault M. L., Männistö P. T., Robinson S., Palmiter R. D., Tallerico T., Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proceedings of the National Academy of Sciences of the United States of America 2005 102 9 3513 3518 2-s2.0-20044378114 10.1073/pnas.0409766102 (Pubitemid 40328076)
17. Seeman P., Guan H.-C., Hirbec H., Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 2009 63 8 698 704 2-s2.0-67650410021 10.1002/syn.20647
18. Moghaddam B., Javitt D., From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012 37 1 4 15 2-s2.0-84856120944 10.1038/npp.2011.181
19. Javitt D. C., Zukin S. R., Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991 148 10 1301 1308 2-s2.0-0025952455
20. Harrison P. J., Weinberger D. R., Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry 2005 10 1 40 68 2-s2.0-12344327212 10.1038/sj.mp.4001558 (Pubitemid 40139588)
21. Pitcher G. M., Kalia L. V., Ng D., Goodfellow N. M., Yee K. T., Lambe E. K., Salter M. W., Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nature Medicine 2011 17 4 470 478 2-s2.0-79953751193 10.1038/nm.2315
22. Collier D. A., Li T., The genetics of schizophrenia: glutamate not dopamine? European Journal of Pharmacology 2003 480 1-3 177 184 2-s2.0-0242499301 10.1016/j.ejphar.2003.08.105 (Pubitemid 37410370)
23. Patil S. T., Zhang L., Martenyi F., Lowe S. L., Jackson K. A., Andreev B. V., Avedisova A. S., Bardenstein L. M., Gurovich I. Y., Morozova M. A., Mosolov S. N., Neznanov N. G., Reznik A. M., Smulevich A. B., Tochilov V. A., Johnson B. G., Monn J. A., Schoepp D. D., Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 2007 13 9 1102 1107 (Pubitemid 47517511)
24. Kantrowitz J. T., Javitt D. C., Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clinical Schizophrenia & Related Psychoses 2010 4 3 189 200 2-s2.0-77957674463 10.3371/CSRP.4.3.6
25. Adell A., Jiménez-Sánchez L., López-Gil X., Romón T., Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophrenia Bulletin 2012 38 1 9 14 10.1093/schbul/sbr133
26. Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren S. I., Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. European Journal of Neurology 2005 12 5 392 398 2-s2.0-17144406339 10.1111/j.1468-1331.2004.00976.x (Pubitemid 40524182)
27. Winter J. C., Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology 2009 203 2 251 263 2-s2.0-62449340237 10.1007/s00213-008-1356-8
28. Geyer M. A., Vollenweider F. X., Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences 2008 29 9 445 453 2-s2.0-55849099288 10.1016/j.tips.2008.06.006
29. Glennon R. A., Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 1990 3 5-6 509 517 2-s2.0-0025602917
30. Vollenweider F. X., Kometer M., The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience 2010 11 9 642 651 2-s2.0-77955961228 10.1038/nrn2884
31. González-Maeso J., Sealfon S. C., Psychedelics and schizophrenia. Trends in Neurosciences 2009 32 4 225 232 2-s2.0-63349093632 10.1016/j.tins.2008.12.005
32. Baumeister A. A., Hawkins M. F., The serotonin hypothesis of schizophrenia: a historical case study on the heuristic value of theory in clinical neuroscience. Journal of the History of the Neurosciences 2004 13 3 277 291 2-s2.0-8144229605 10.1080/09647040490510560 (Pubitemid 39473018)
33. Studerus E., Kometer M., Hasler F., Vollenweider F. X., Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology 2011 25 11 1434 1452 2-s2.0-83455162367 10.1177/0269881110382466
34. Lera G., Herrero N., González J., Aguilar E., Sanjuán J., Leal C., Insight among psychotic patients with auditory hallucinations. Journal of Clinical Psychology 2011 67 7 701 708 2-s2.0-79958041550 10.1002/jclp.20799
35. Meltzer H. Y., Massey B. W., The role of serotonin receptors in the action of atypical antipsychotic drugs. Current Opinion in Pharmacology 2011 11 1 59 67 2-s2.0-79953689886 10.1016/j.coph.2011.02.007
36. Javitt D. C., Glutamate and schizophrenia: phencyclidine, N -methyl-d-aspartate receptors, and dopamine-glutamate interactions. International Review of Neurobiology 2007 78 69 108 2-s2.0-33847355523 10.1016/S0074-7742(06)78003-5
37. Li M., He E., Volf N., Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment. Pharmacology Biochemistry and Behavior 2011 98 4 559 569 2-s2.0-79953116125 10.1016/j.pbb.2011.03.007
38. Swerdlow N. R., Weber M., Qu Y., Light G. A., Braff D. L., Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 2008 199 3 331 388 2-s2.0-46649110318 10.1007/s00213-008-1072-4
39. del Arco A., Mora F., Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacology Biochemistry and Behavior 2008 90 2 226 235 2-s2.0-44649139791 10.1016/j.pbb.2008.04.011
40. Gaiardi M., Gubellini C., Dall'Olio R., Gandolfi O., Bartoletti M., Effects of N -methyl-d-aspartate agonists and antagonists in rats discriminating amphetamine. Behavioural Pharmacology 2001 12 5 317 324 2-s2.0-0034774736 (Pubitemid 32983504)
41. Matulewicz P., Kasicki S., Hunt M. J., The effect of dopamine receptor blockade in the rodent nucleus accumbens on local field potential oscillations and motor activity in response to ketamine. Brain Research 2010 1366 226 232 2-s2.0-79251638784 10.1016/j.brainres.2010.09.088
42. 2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 2001 76 5 1521 1531 2-s2.0-0035096016 10.1046/j.1471-4159.2001.00154.x (Pubitemid 32198256)
43. Leucht S., Corves C., Arbter D., Engel R. R., Li C., Davis J. M., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet 2009 373 9657 31 41 2-s2.0-58049157203 10.1016/S0140-6736(08)61764-X
44. Marona-Lewicka D., Nichols D. E., Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacology Biochemistry and Behavior 2007 87 4 453 461 2-s2.0-34547838201 10.1016/j.pbb.2007.06.001 (Pubitemid 47243674)
45. 2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology 2005 180 3 427 435 2-s2.0-21344473041 10.1007/s00213-005-2183-9 (Pubitemid 40905032)
46. Bortolozzi A., Díaz-Mataix L., Scorza M. C., Celada P., Artigas F., The activation of 5-HT2A receptors in prefrontal cortex enhances dopaminergic activity. Journal of Neurochemistry 2005 95 6 1597 1607 2-s2.0-28044457735 10.1111/j.1471-4159.2005.03485.x (Pubitemid 41804057)
47. 2 receptors. Neuropharmacology 2011 61 4 770 777 2-s2.0-79959993845 10.1016/j.neuropharm.2011.05.023
48. Vollenweider F. X., Vollenweider-Scherpenhuyzen M. F. I., Bäbler A., Vogel H., Hell D., Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998 9 17 3897 3902 2-s2.0-0032430801 (Pubitemid 29189323)
49. Kometer M., Schmidt A., Jäncke L., Vollenweider F. X., Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. The Journal of Neuroscience 2013 33 25 10544 10551 10.1523/JNEUROSCI.3007-12.2013
50. Gouzoulis-Mayfrank E., Heekeren K., Neukirch A., Stoll M., Stock C., Daumann J., Obradovic M., Kovar K.-A., Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology 2006 31 2 431 441 2-s2.0-30944463238 10.1038/sj.npp.1300882 (Pubitemid 43113407)
51. Heekeren K., Daumann J., Neukirch A., Stock C., Kawohl W., Norra C., Waberski T. D., Gouzoulis-Mayfrank E., Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology 2008 199 1 77 88 2-s2.0-46149109833 10.1007/s00213-008-1129-4
52. Heekeren K., Neukirch A., Daumann J., Stoll M., Obradovic M., Kovar K.-A., Geyer M. A., Gouzoulis-Mayfrank E., Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. Journal of Psychopharmacology 2007 21 3 312 320 2-s2.0-34250674024 10.1177/0269881107077734 (Pubitemid 46934051)
53. Dall'Olio R., Gaggi R., Bonfante V., Gandolfi O., The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behavioural Pharmacology 1999 10 1 63 71 2-s2.0-0033010654 (Pubitemid 29106289)
54. Dall'Olio R., Gandolfi O., Gaggi R., D-cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function. Behavioural Pharmacology 2000 11 7-8 631 637 2-s2.0-0033635444
55. González-Maeso J., Ang R. L., Yuen T., Chan P., Weisstaub N. V., López-Giménez J. F., Zhou M., Okawa Y., Callado L. F., Milligan G., Gingrich J. A., Filizola M., Meana J. J., Sealfon S. C., Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008 452 7183 93 97 2-s2.0-40449139964 10.1038/nature06612 (Pubitemid 351355090)
56. Homayoun H., Jackson M. E., Moghaddam B., Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. Journal of Neurophysiology 2005 93 4 1989 2001 2-s2.0-15544385061 10.1152/jn.00875.2004 (Pubitemid 40404399)
57. Fell M. J., McKinzie D. L., Monn J. A., Svensson K. A., Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 2012 62 3 1473 1483 2-s2.0-84856097892 10.1016/j.neuropharm.2011.06.007
58. Marek G. J., Behl B., Bespalov A. Y., Gross G., Lee Y., Schoemaker H., Glutamatergic (N -methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Molecular Pharmacology 2010 77 3 317 326
59. Dall'Olio R., Gandolfi O., Gaggi R., Blockade of the serotonergic system counteracts the dizocilpine-induced changes in dopaminergic function. Behavioural Pharmacology 2000 11 1 29 36 2-s2.0-0033999025 (Pubitemid 30223755)
60. Fletcher P. C., Frith C. D., Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nature Reviews Neuroscience 2009 10 1 48 58 2-s2.0-57749177083 10.1038/nrn2536
61. Gaebel W., Zielasek J., Future classification of psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience 2009 259 supplement 2 S213 S218 2-s2.0-73449089470 10.1007/s00406-009-0049-6
62. Daalman K., van Zandvoort M., Bootsman F., Boks M., Kahn R., Sommer I., Auditory verbal hallucinations and cognitive functioning in healthy individuals. Schizophrenia Research 2011 132 2-3 203 207 2-s2.0-81155161944 10.1016/j.schres.2011.07.013
63. van der Zwaard R., Polak M. A., Pseudohallucinations: a pseudoconcept? A review of the validity of the concept, related to associate symptomatology. Comprehensive Psychiatry 2001 42 1 42 50 2-s2.0-0035156944 10.1053/comp.2001. 19752 (Pubitemid 32095063)
64. Studerus E., Gamma A., Kometer M., Vollenweider F. X., Prediction of psilocybin response in healthy volunteers. PLoS ONE 2012 7 2, article e30800 2-s2.0-84857184881 10.1371/journal.pone.0030800
65. Huot P., Johnston T. H., Darr T., Hazrati L.-N., Visanji N. P., Pires D., Brotchie J. M., Fox S. H., Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Movement Disorders 2010 25 10 1399 1408 2-s2.0-77954961146 10.1002/mds.23083
66. Kometer M., Cahn B. R., Andel D., Carter O. L., Vollenweider F. X., The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biological Psychiatry 2011 69 5 399 406 2-s2.0-79951618473 10.1016/j.biopsych.2010.10.002
67. Carhart-Harris R. L., Erritzoe D., Williams T., Stone J. M., Reed L. J., Colasanti A., Tyacke R. J., Leech R., Malizia A. L., Murphy K., Hobden P., Evans J., Feilding A., Wise R. G., Nutt D. J., Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America 2012 109 6 2138 2143 2-s2.0-84857129869 10.1073/pnas.1119598109
68. Scheidegger M., Walter M., Lehmann M., Metzger C., Grimm S., Boeker H., Boesiger P., Henning A., Seifritz E., Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS ONE 2012 7 9, article e44799 2-s2.0-84866720097 10.1371/journal.pone.0044799
69. Lee U., Kim S., Noh G.-J., Choi B.-M., Hwang E., Mashour G. A., The directionality and functional organization of frontoparietal connectivity during consciousness and anesthesia in humans. Consciousness and Cognition 2009 18 4 1069 1078 2-s2.0-70349121163 10.1016/j.concog.2009.04.004
70. Butler T. C., Benayoun M., Wallace E., van Drongelenc W., Goldenfelda N., Cowane J., Evolutionary constraints on visual cortex architecture from the dynamics of hallucinations. Proceedings of the National Academy of Sciences of the United States of America 2012 109 2 606 609 2-s2.0-84855991259 10.1073/pnas.1118672109
71. Waters F., Collerton D., Ffytche D., Jardri R., Pins D., Dudley R., Blom J. D., Mosimann U. P., Eperjesi F., Ford S., Larøi F., Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease. Schizophrenia Bulletin 2014 10.1093/schbul/sbu036
72. Jardri R., Thomas P., Delmaire C., Delion P., Pins D., The neurodynamic organization of modality-dependent hallucinations. Cerebral Cortex 2013 23 5 1108 1117 2-s2.0-84876179070 10.1093/cercor/bhs082